Dr. Reddy's Laboratories Limited

rs,

he Governments in our key global markets; Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry; Increasing competition in and the conditions of our cus

17%

IGHLIGHTS  Highest ever quarterly revenues & profits in Q4  Double-digit FY25 Revenue growth at 17%  Underlying growth excl. acquired Consumer healthcare (NRT) business @12%  Robust FY25 EBITDA

12%

Y25 Revenue growth at 17%  Underlying growth excl. acquired Consumer healthcare (NRT) business @12%  Robust FY25 EBITDA and RoCE at 28%  A strong balance sheet with Net cash surplus of ₹2,454 Cr

28%

g growth excl. acquired Consumer healthcare (NRT) business @12%  Robust FY25 EBITDA and RoCE at 28%  A strong balance sheet with Net cash surplus of ₹2,454 Cr Q4 Performance FY25 Performance ₹ 8

₹2,454

iness @12%  Robust FY25 EBITDA and RoCE at 28%  A strong balance sheet with Net cash surplus of ₹2,454 Cr Q4 Performance FY25 Performance ₹ 8,506 Cr Revenues ₹ 32,554 Cr Revenues 20%YoY 2% QoQ 1

₹ 8,506

28%  A strong balance sheet with Net cash surplus of ₹2,454 Cr Q4 Performance FY25 Performance ₹ 8,506 Cr Revenues ₹ 32,554 Cr Revenues 20%YoY 2% QoQ 17%YoY ₹ 2,475 Cr | 29% EBITDA | EBITDA % ₹ 9

₹ 32,554

e sheet with Net cash surplus of ₹2,454 Cr Q4 Performance FY25 Performance ₹ 8,506 Cr Revenues ₹ 32,554 Cr Revenues 20%YoY 2% QoQ 17%YoY ₹ 2,475 Cr | 29% EBITDA | EBITDA % ₹ 9,213 Cr | 28% EBITDA |

20%

urplus of ₹2,454 Cr Q4 Performance FY25 Performance ₹ 8,506 Cr Revenues ₹ 32,554 Cr Revenues 20%YoY 2% QoQ 17%YoY ₹ 2,475 Cr | 29% EBITDA | EBITDA % ₹ 9,213 Cr | 28% EBITDA | EBITDA % 32%YoY

2%

f ₹2,454 Cr Q4 Performance FY25 Performance ₹ 8,506 Cr Revenues ₹ 32,554 Cr Revenues 20%YoY 2% QoQ 17%YoY ₹ 2,475 Cr | 29% EBITDA | EBITDA % ₹ 9,213 Cr | 28% EBITDA | EBITDA % 32%YoY 8% QoQ

₹ 2,475

Performance FY25 Performance ₹ 8,506 Cr Revenues ₹ 32,554 Cr Revenues 20%YoY 2% QoQ 17%YoY ₹ 2,475 Cr | 29% EBITDA | EBITDA % ₹ 9,213 Cr | 28% EBITDA | EBITDA % 32%YoY 8% QoQ 11%YoY ₹ 2,005 Cr |

29%

FY25 Performance ₹ 8,506 Cr Revenues ₹ 32,554 Cr Revenues 20%YoY 2% QoQ 17%YoY ₹ 2,475 Cr | 29% EBITDA | EBITDA % ₹ 9,213 Cr | 28% EBITDA | EBITDA % 32%YoY 8% QoQ 11%YoY ₹ 2,005 Cr | 24% PBT

₹ 9,213

06 Cr Revenues ₹ 32,554 Cr Revenues 20%YoY 2% QoQ 17%YoY ₹ 2,475 Cr | 29% EBITDA | EBITDA % ₹ 9,213 Cr | 28% EBITDA | EBITDA % 32%YoY 8% QoQ 11%YoY ₹ 2,005 Cr | 24% PBT | PBT % ₹ 7,678 Cr | 24% P